Free Trial
LON:HLN

Haleon (HLN) Share Price, News & Analysis

Haleon logo
GBX 380.50 -2.30 (-0.60%)
As of 04/17/2025 12:04 PM Eastern

About Haleon Stock (LON:HLN)

Key Stats

Today's Range
378.10
381.50
50-Day Range
357.60
415
52-Week Range
319.84
417.70
Volume
15.36 million shs
Average Volume
26.94 million shs
Market Capitalization
£34.34 billion
P/E Ratio
32.00
Dividend Yield
1.58%
Price Target
GBX 457
Consensus Rating
Buy

Company Overview

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges. Haleon's portfolio spans five global categories including Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health and Digestive Health and other. Within these categories, there are long standing-brands – such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, paradontax and Centrum, which are used and trusted by millions of consumers around the world. These brands are built on trusted science, innovation and deep human understanding.

Haleon Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
17th Percentile Overall Score

HLN MarketRank™: 

Haleon scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Haleon has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Haleon has only been the subject of 1 research reports in the past 90 days.

  • Read more about Haleon's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Haleon is 32.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.41.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Haleon is 32.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.94.

  • Price to Earnings Growth Ratio

    Haleon has a PEG Ratio of 1.49. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Haleon has a P/B Ratio of 2.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for HLN.
  • Dividend Yield

    Haleon has a dividend yield of 0.02%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Haleon does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Haleon is 50.46%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Read more about Haleon's dividend.
  • Short Interest

    There is no current short interest data available for HLN.
  • Search Interest

    Only 3 people have searched for HLN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Haleon to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Haleon insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.74% of the stock of Haleon is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    43.88% of the stock of Haleon is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Haleon's insider trading history.
Receive HLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Haleon and its competitors with MarketBeat's FREE daily newsletter.

HLN Stock News Headlines

Haleon climbs Tuesday, outperforms market
Haleon slips Monday, underperforms market
Trump and Musk fight back
Is there more to the Musk–Trump relationship than meets the eye? Jeff Brown thinks so — and he believes it has to do with a top-level initiative to build the ultimate military-grade AI system. He’s calling it the “AI Superweapon,” and he says it could soon become the center of global tech dominance. At the core of this initiative? A handful of companies tied to America’s most powerful tech platforms — and investors who act before this goes mainstream may have a rare early edge.
Kepler Capital Reaffirms Their Buy Rating on Haleon PLC (HLN)
Pfizer to sell entire Haleon stake
Haleon slips Wednesday, underperforms market
Haleon slides Wednesday, underperforms market
See More Headlines

HLN Stock Analysis - Frequently Asked Questions

Haleon's stock was trading at GBX 377.40 at the start of the year. Since then, HLN shares have increased by 0.8% and is now trading at GBX 380.50.
View the best growth stocks for 2025 here
.

Haleon plc (LON:HLN) announced its quarterly earnings data on Friday, February, 28th. The company reported $15.80 EPS for the quarter. Haleon had a net margin of 9.66% and a trailing twelve-month return on equity of 6.54%.

Shares of HLN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Haleon investors own include GSK (GSK), Micron Technology (MU), NVIDIA (NVDA), AT&T (T), Cisco Systems (CSCO), Meta Platforms (META) and Unilever (ULVR).

Company Calendar

Last Earnings
2/28/2025
Today
4/20/2025
Record date for 6/5 Dividend
4/24/2025
Ex-Dividend for 6/5 Dividend
4/24/2025
Dividend Payable
6/05/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
Consumer Goods
Current Symbol
LON:HLN
CIK
N/A
Fax
N/A
Employees
25,408
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 457
High Stock Price Target
GBX 457
Low Stock Price Target
GBX 457
Potential Upside/Downside
+20.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
32.00
Forward P/E Ratio
19.51
P/E Growth
1.49
Net Income
£1.07 billion
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£11.07 billion
Cash Flow
GBX 17.33 per share
Price / Cash Flow
21.95
Book Value
GBX 182.02 per share
Price / Book
2.09

Miscellaneous

Outstanding Shares
9,025,597,051
Free Float
N/A
Market Cap
£34.34 billion
Optionable
Not Optionable
Beta
0.19
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (LON:HLN) was last updated on 4/20/2025 by MarketBeat.com Staff
From Our Partners